Artivion, Inc. (NYSE:AORT) Position Reduced by CANADA LIFE ASSURANCE Co

CANADA LIFE ASSURANCE Co lessened its stake in Artivion, Inc. (NYSE:AORT - Free Report) by 28.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 36,890 shares of the company's stock after selling 14,756 shares during the quarter. CANADA LIFE ASSURANCE Co owned approximately 0.09% of Artivion worth $1,055,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of AORT. Wasatch Advisors LP lifted its position in shares of Artivion by 27.7% in the 4th quarter. Wasatch Advisors LP now owns 1,041,992 shares of the company's stock worth $29,791,000 after buying an additional 226,160 shares during the last quarter. Lord Abbett & CO. LLC acquired a new stake in Artivion during the third quarter worth about $5,798,000. Tidal Investments LLC lifted its holdings in Artivion by 602.2% in the third quarter. Tidal Investments LLC now owns 157,002 shares of the company's stock worth $4,179,000 after acquiring an additional 134,642 shares during the last quarter. Next Century Growth Investors LLC boosted its stake in Artivion by 29.7% in the fourth quarter. Next Century Growth Investors LLC now owns 492,653 shares of the company's stock valued at $14,085,000 after acquiring an additional 112,918 shares during the period. Finally, JPMorgan Chase & Co. grew its holdings in shares of Artivion by 394.9% during the third quarter. JPMorgan Chase & Co. now owns 97,903 shares of the company's stock valued at $2,606,000 after purchasing an additional 78,120 shares during the last quarter. Institutional investors own 86.37% of the company's stock.

Artivion Price Performance

AORT traded up $0.03 on Friday, reaching $23.36. The company had a trading volume of 253,995 shares, compared to its average volume of 301,834. The company has a market capitalization of $997.22 million, a P/E ratio of -1,168.00 and a beta of 1.65. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71. The company has a fifty day moving average of $23.95 and a 200-day moving average of $27.20. Artivion, Inc. has a one year low of $20.64 and a one year high of $32.33.

Artivion (NYSE:AORT - Get Free Report) last posted its quarterly earnings data on Monday, February 24th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.51). Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. The company had revenue of $97.31 million during the quarter, compared to the consensus estimate of $100.82 million. As a group, equities research analysts anticipate that Artivion, Inc. will post 0.37 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms recently issued reports on AORT. Needham & Company LLC reduced their price objective on Artivion from $34.00 to $32.00 and set a "buy" rating for the company in a research report on Tuesday, February 25th. Stifel Nicolaus dropped their price objective on shares of Artivion from $33.00 to $30.00 and set a "buy" rating on the stock in a report on Tuesday, February 25th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $31.40.

Insider Activity

In related news, SVP Jean F. Holloway sold 5,335 shares of the business's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $27.31, for a total value of $145,698.85. Following the sale, the senior vice president now directly owns 149,799 shares in the company, valued at $4,091,010.69. The trade was a 3.44 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO James P. Mackin sold 42,156 shares of the stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $27.31, for a total transaction of $1,151,280.36. Following the sale, the chief executive officer now directly owns 663,882 shares of the company's stock, valued at approximately $18,130,617.42. This represents a 5.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 90,799 shares of company stock worth $2,356,223. 7.60% of the stock is owned by company insiders.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.